Arkolith/Insider Trading/KNSA/Form 4

Levy Richard S

DirectorKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Feb 4, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2026Option exercise(M)683——19K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2026Option exercise(M)683—$00
Feb 1, 2026Grant(A)683—$0683

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001454983-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML